ReviewJournal of experimental pharmacology2015
Current knowledge on the neuroprotective and neuroregenerative properties of citicoline in acute ischemic stroke.
Review in Journal of experimental pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- The efficacy of different doses of citicoline in improving the prognosis of patients with acute ischemic stroke based on network meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Citicoline for treating people with acute ischemic stroke.The Cochrane database of systematic reviews · 2020Pooled it
- Trial
- Unveiling the "Glycolysis-Lactate-Lactylation" Axis: A Novel Target in Ischemic Cerebrovascular Disease.Neuroscience bulletin · 2026Review
- Effect of Citicoline Loaded PHBA Tubular Grafts on Axonal Regeneration in Sciatic Nerve Injury : An Experimental Approach as an Autograft Alternative.Journal of Korean Neurosurgical Society · 2026Article
- Phytochemical and Fungal Bioactive Compounds in the "Brain Health Triad": A Narrative Review on Neurostimulating, Neurotrophic, and Neuroprotective Synergy.International journal of molecular sciences · 2026Review
- The effect of citicoline administration on visual function improvement in stroke patients at Prof. Dr. Chairuddin Panusunan Lubis Hospital, University of Sumatera Utara, and affiliated network hospitals.Frontiers in medicine · 2026Article
- Integrated analysis of m6A regulator mediated RNA methylation and key immune related genes in ischemic stroke.Scientific reports · 2025Article
- Association between serum lactate and mortality in critically ill ischemic stroke patients based on MIMIC-IV data.Scientific reports · 2025Article
- Lactylation and Ischemic Stroke: Research Progress and Potential Relationship.Molecular neurobiology · 2025Review
- Annexin A1: The dawn of ischemic stroke (Review).Molecular medicine reports · 2025Review
- Significance of Neurotransmitters in Cerebral Ischemia: Understanding the Role of Serotonin, Dopamine, Glutamate, and GABA in Stroke Recovery and Treatment.Central nervous system agents in medicinal chemistry · 2025Review
- Therapeutic management of ischemic stroke.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Investigation of relayed nuclear Overhauser enhancement effect at -1.6 ppm in an ischemic stroke model.Quantitative imaging in medicine and surgery · 2023Article
- Citicoline and COVID-19: vis-à-vis conjectured.Naunyn-Schmiedeberg's archives of pharmacology · 2022Review
- Citicoline: pharmacological and clinical review, 2022 update.Revista de neurologia · 2022Review
- Focus on the role of mitochondria in NLRP3 inflammasome activation: A prospective target for the treatment of ischemic stroke (Review).International journal of molecular medicine · 2022Review
- Molecular and anatomical roadmap of stroke pathology in immunodeficient mice.Frontiers in immunology · 2022Article
- Genomics as a Clinical Decision Support Tool for Identifying and Addressing Modifiable Causes of Cognitive Decline and Improving Outcomes: Proof of Concept Support for This Personalized Medicine Strategy.Frontiers in aging neuroscience · 2022Article
- Citicoline and COVID-19-Related Cognitive and Other Neurologic Complications.Brain sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke is one of the leading causes of long-lasting disability and death. Two main strategies have been proposed for the treatment of ischemic stroke: restoration of blood flow by thrombolysis or mechanical thrombus extraction during the first few hours of ischemic stroke, which is one of the most effective treatments and leads to a better functional and clinical outcome. The other direction of treatment, which is potentially applicable to most of the patients with ischemic stroke, is neuroprotection. Initially, neuroprotection was mainly targeted at protecting gray matter, but during the past few years there has been a transition from a neuron-oriented approach toward salvaging the whole neurovascular unit using multimodal drugs. Citicoline is a multimodal drug that exhibits neuroprotective and neuroregenerative effects in a variety of experimental and clinical disorders of the central nervous system, including acute and chronic cerebral ischemia, intracerebral hemorrhage, and global cerebral hypoxia. Citicoline has a prolonged therapeutic window and is active at various temporal and biochemical stages of the ischemic cascade. In acute ischemic stroke, citicoline provides neuroprotection by attenuating glutamate exitotoxicity, oxidative stress, apoptosis, and blood-brain barrier dysfunction. In the subacute and chronic phases of ischemic stroke, citicoline exhibits neuroregenerative effects and activates neurogenesis, synaptogenesis, and angiogenesis and enhances neurotransmitter metabolism. Acute and long-term treatment with citicoline is safe and in most clinical studies is effective and improves functional outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.